Aldose reductase (AR) is an NADPH-dependent aldo-keto reductase that has been shown to be involved in the pathogenesis of several blinding diseases such as uveitis, diabetic retinopathy (DR) and cataract. However, possible mechanisms linking the action of AR to these diseases are not well understood. As DR and cataract are among the leading causes of blindness in the world, there is an urgent need to explore therapeutic strategies to prevent or delay their onset. Studies with AR inhibitors and gene-targeted mice have demonstrated that the action of AR is also linked to cancer onset and progression. In this review we examine possible mechanisms that relate AR to molecular signaling cascades and thus explain why AR inhibition is an effective strategy against colon cancer as well as diseases of the eye such as uveitis, cataract, and retinopathy.
CITATION STYLE
Chang, K. C., & Petrash, J. M. (2018). Aldo-keto reductases: Multifunctional proteins as therapeutic targets in diabetes and inflammatory disease. In Advances in Experimental Medicine and Biology (Vol. 1032, pp. 173–202). Springer New York LLC. https://doi.org/10.1007/978-3-319-98788-0_13
Mendeley helps you to discover research relevant for your work.